Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why Lexicon Pharmaceuticals Is Down 11% Today

TheMotleyFool

0 0

Why Lexicon Pharmaceuticals Is Down 11% Today

After Lexicon Pharmaceuticals (NASDAQ: LXRX) announced yesterday the publication of phase 3 results for its lead diabetes drug, sotagliflozin, in the New England Journal of Medicine, its shares are losing 11% of their value at 11:45 a.m. EDT.

Sotagliflozin is a novel diabetes drug that attempts to improve glycemic control by targeting both SGLT1 and SGLT2 for the first time.

IMAGE SOURCE: GETTY IMAGES.

Source: Fool.com